Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CD19/NKG2DL CAR-T Therapeutic

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Celyad Oncology

Drug class:

CD19-targeted CAR-T immunotherapy, NKG2D-targeted CAR-T immunotherapy

Related drugs:

‹

KD-025 CAR T-cells (0)

NKG2D CAR T-cells (0)

axicabtagene ciloleucel (24)

lisocabtagene maraleucel (23)

tisagenlecleucel-T (15)

brexucabtagene autoleucel (4)

relmacabtagene autoleucel (2)

obecabtagene autoleucel (1)

CAR-T19/CAR-T22 immunotherapy (1)

Anti-CD19 CAR-T (0)

Anti-CD19-CAR (0)

Anti-CD19/CD20/CD22 CAR T-Cells (0)

Autologous CAR-T cells (0)

CAR-20/19-T Cells (0)

CAR-T CD19/CD20/CD22/CD30 (0)

CAR19T2 T cells (0)

CAR20.19.22 T (0)

CARCIK-CD19 (0)

CART-138/BCMA/19/more (0)

CD19 CAR T cells (0)

CD19 UCART cells (0)

CD19 and CD22 targeted prime CAR-T (0)

CD19 targeted CAR-T (0)

CD19-7×19 CAR-T (0)

CD19-CAR-DNT (0)

CD19-CAR-T2 cells (0)

CD19-CAR.CD45RA- negative T-cells (0)

CD19-CAR_Lenti T cells (0)

CD19-CD22 CAR-T (0)

CD19-CD34 CAR transduced T cells (0)

CD19-CD34t metabolically programmed CAR transduced T-cells (0)

CD19-PD1-CART cell (0)

CD19-targeted CAR-T cells (0)

CD19/BAFF-R dual CAR T (0)

CD19/BCMA targeted CAR T-cells (0)

CD19/CD20 CAR T-cells (0)

CD19/CD22 CAR T-cells (0)

CD19/CD22 CAR-T cell therapy (0)

CD19/CD22 chimeric antigen receptor T cell (0)

CD19/CD22 dual-target CAR-T (0)

CD19CAR/virus specific T cell therapy (0)

CD19x22 CAR T (0)

CD20-CD19 cCAR T cells (0)

CD22/CD19 CAR T (0)

CLBR001/SWI019 (0)

CMV/CD19 bi-Specific CAR T (0)

CTA30X UCAR-T (0)

DDCAR-CD19 T-cells (0)

EGFRt/19-28z/4-1BBL CAR T cells (0)

IM19 CAR-T cells (0)

MB-CAR-T19-22 (0)

MB-CART 19.1 (0)

RPM CD19-mbIL15-CAR-T cells (0)

anbalcabtagene autoleucel (0)

SCRI-CAR19x22v2 (0)

SCRI-huCAR19v1 (0)

SCRI-huCAR19v2 (0)

SNUH-CD19-CAR-T (0)

STK-009/SYNCAR-001 (0)

Senl_H19x22P (0)

ThisCART19A (0)

UCD19 CAR T Cells (0)

XYF19 CAR-T cells (0)

inaticabtagene autoleucel (0)

alloCART-19 cell therapy (0)

anti-CD19 CAR-T cell therapy (0)

anti-CD19 CAR-T cell therapy (0)

anti-CD19 CAR-T therapy (0)

anti-CD19 DASH CAR-T (0)

anti-CD19-CAR (0)

anti-CD19-CAR γδT (0)

anti-CD19/CD22 CAR-T cells (0)

autologous 3rd generation CD19-targeting CAR T cell therapy (0)

autologous TriCAR T (0)

human derived (0)

huCART19-IL18 (0)

human anti CD19 CAR-T cells (0)

humanized CD19 CAR-T cell therapy (0)

iC9-CAR19 cells (0)

multi-CAR-T cell therapy (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

murine CD19 CAR-T cell therapy (0)

murine autologous anti-CD19 CART cells (0)

sequential different B cell antigen-targeted CAR T-cell therapy (0)

MB-CART2019.1 (0)

KD-025 CAR T-cells (0)

NKG2D CAR T-cells (0)

›

over1year

NKG2D-Based Dual CAR T Cells to Overcome Antigen Escape and Improve AntiTumor Efficacy (IO-SUMMIT EUROPE 2023)

In vitro, T cells transduced with these constructs displayed cytotoxic activity, proliferated, and secreted cytokines in presence of WT and CD19 KO B-ALL cancer cells. Since NKG2DL are expressed in many cancer indications and absent from healthy tissues, use of NKG2DL-based dual CAR T cells is an attractive approach to improve anti-tumor efficacy in solid indications.

over 1 year ago

Clinical • CAR T-Cell Therapy

|

NKG2D (killer cell lectin like receptor K1)

|

CD19/NKG2DL CAR-T Therapeutic